An mHealth mood management tool to improve population-level tobacco cessation
一种改善人群戒烟水平的移动健康情绪管理工具
基本信息
- 批准号:10632755
- 负责人:
- 金额:$ 11.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY
Cigarette smoking is responsible for over 480,000 deaths annually in the US—three times higher than drug
overdose- and alcohol-related deaths combined—making cigarettes the most deadly drug of abuse. Although
smoking rates have declined over the past 50 years, tobacco use remains a critical problem. Depression
symptoms, which are highly prevalent among smokers making a quit attempt, reduce the odds of cessation by
50% and are not addressed in standard interventions. New methods for addressing depressive symptoms in
the context of a quit attempt are greatly needed. Behavioral activation therapy for depression (BAT-D) is a
novel addition to standard smoking cessation interventions that can address depressive symptoms as a risk
factor for treatment failure. Delivery through a mobile health application (mHealth app) makes this targeted
treatment available in a high-reach format, as apps for smoking cessation are downloaded over 1.6 million
times per year in the US alone. We conducted focus groups and individual user interviews to develop a limited
prototype of a BAT-D mood management app called Actify. We then evaluated it in a single-arm pilot trial,
which showed high engagement with the app (mean number of app logins=20), a promising short-term quit
rate of 31%, and a statistically and clinically significant reduction in depression symptoms. In this study, we
propose to refine the app based on single-arm pilot data, integrate smoking cessation content, conduct
usability testing, and evaluate the acceptability and efficacy of the completed app in a pilot randomized
controlled trial. In the first phase of the study, we will complete the development of Actify by adding cessation
content, refining the app structure to improve usability, and conducting additional prototype testing with a small
group of smokers (n=15). The second phase will be a pilot, randomized, controlled trial (n=240) comparing
Actify with QuitGuide, the National Cancer Institute’s mHealth app for smoking cessation, on (a) acceptability
(user satisfaction and number of app logins), (b) smoking abstinence (primary endpoint of 30-day point
prevalence abstinence at 8 weeks post-randomization), and (c) mechanisms of change (depressive symptoms
and change in behavioral activation). This study is significant in that addresses the important public health
problem of low quit rates and resultant tobacco-related health disparities among smokers experiencing mood
symptoms, and it builds off of a growing body of literature supporting the value of behavioral activation as a
component of cessation counseling. It is innovative in several key respects, including: (1) Actify is the first
standalone mHealth intervention of any kind to target depression and smoking cessation simultaneously; (2) it
is the first pilot trial of a standalone mHealth app to address depression as a barrier to quitting smoking; and,
(3) mHealth apps are a novel and promising addition to the larger body of mHealth research on text
messaging, which has demonstrated efficacy. This project will generate pilot data to support an R01-level
project testing the effectiveness of Actify in a fully-powered, randomized controlled trial.
项目摘要
在美国,吸烟每年导致48万人死亡,是吸毒死亡人数的三倍。
过量和酒精相关的死亡加在一起,使香烟成为最致命的滥用药物。虽然
尽管吸烟率在过去50年中有所下降,但烟草使用仍然是一个严重问题。抑郁
在尝试戒烟的吸烟者中非常普遍的症状,通过以下方式降低戒烟的几率:
50%,在标准干预措施中没有得到解决。治疗抑郁症的新方法
非常需要退出尝试的上下文。抑郁症的行为激活疗法(BAT-D)是一种
标准戒烟干预措施的新补充,可将抑郁症状作为风险解决
治疗失败的因素。通过移动的健康应用程序(mHealth应用程序)提供服务,
戒烟应用程序下载量超过160万次,
每年仅在美国就有10次。我们进行了焦点小组和个人用户访谈,
BAT-D情绪管理应用程序Actify的原型。然后我们在一个单臂试验中对其进行了评估,
这显示了对应用程序的高参与度(平均应用程序登录次数=20),这是一个有希望的短期退出
率为31%,抑郁症状在统计学和临床上显著减少。本研究
建议根据单臂试点数据完善应用程序,整合戒烟内容,
可用性测试,并在试点随机化中评估完整应用程序的可接受性和有效性
对照试验在研究的第一阶段,我们将通过添加戒烟功能来完成Actify的开发
内容,改进应用程序结构以提高可用性,并使用小型
吸烟组(n=15)。第二阶段将是一项初步、随机、对照试验(n=240),比较
使用国家癌症研究所的戒烟mHealth应用程序QuitGuide激活(a)可接受性
(user满意度和应用程序登录次数),(B)戒烟(30天时间点的主要终点
随机分组后8周的戒烟率),以及(c)变化机制(抑郁症状
和行为激活的变化)。这项研究的意义在于解决了重要的公共卫生问题,
戒烟率低的问题以及由此导致的吸烟者与烟草有关的健康差异
症状,它建立在越来越多的文献基础上,这些文献支持行为激活作为一种
停止咨询的组成部分。它在几个关键方面具有创新性,包括:(1)Actify是第一个
同时针对抑郁症和戒烟的任何形式的独立移动健康干预;(2)它
是第一个独立的移动健康应用程序的试点试验,以解决抑郁症作为戒烟的障碍;
(3)移动健康应用程序是一个新的和有前途的除了更大的身体移动健康研究的文本
消息传递,这已经证明了有效性。该项目将生成试验数据,以支持R 01级
在一项完全把握度的随机对照试验中测试Actify有效性的项目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jaimee Heffner其他文献
Jaimee Heffner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jaimee Heffner', 18)}}的其他基金
ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation
ACT on Vaping:针对年轻人戒烟的数字疗法
- 批准号:
10533937 - 财政年份:2022
- 资助金额:
$ 11.85万 - 项目类别:
An mHealth mood management tool to improve population-level tobacco cessation
一种改善人群戒烟水平的移动健康情绪管理工具
- 批准号:
10217089 - 财政年份:2020
- 资助金额:
$ 11.85万 - 项目类别:
An mHealth mood management tool to improve population-level tobacco cessation
一种改善人群戒烟水平的移动健康情绪管理工具
- 批准号:
10436829 - 财政年份:2020
- 资助金额:
$ 11.85万 - 项目类别:
A Scalable e-Health Smoking Cessation Intervention for Socioeconomically Disadvantaged Veterans
针对社会经济弱势退伍军人的可扩展电子健康戒烟干预措施
- 批准号:
9912129 - 财政年份:2019
- 资助金额:
$ 11.85万 - 项目类别:
Web-Delivered Acceptance & Commitment Therapy for Smokers with Bipolar Disorder
网络交付验收
- 批准号:
8951982 - 财政年份:2015
- 资助金额:
$ 11.85万 - 项目类别:
Web-Delivered Acceptance & Commitment Therapy for Smokers with Bipolar Disorder
网络交付验收
- 批准号:
9116810 - 财政年份:2015
- 资助金额:
$ 11.85万 - 项目类别:
相似海外基金
Role of intestinal serotonin transporter in post traumatic stress disorder
肠道血清素转运蛋白在创伤后应激障碍中的作用
- 批准号:
10590033 - 财政年份:2024
- 资助金额:
$ 11.85万 - 项目类别:
NeuroMAP Phase II - Administrative Core
NeuroMAP 第二阶段 - 管理核心
- 批准号:
10711135 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别:
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
- 批准号:
10723233 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别:
A Novel Assay to Improve Translation in Analgesic Drug Development
改善镇痛药物开发转化的新方法
- 批准号:
10726834 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别:
Feasibility of a care team-focused action plan to improve quality of care for children and adolescents with inflammatory bowel disease
以护理团队为重点的行动计划的可行性,以提高炎症性肠病儿童和青少年的护理质量
- 批准号:
10724900 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别:
Early Detection of Right Ventricular Dysfunction and Emerging Pulmonary Hypertension in Systemic Sclerosis
系统性硬化症患者右心室功能障碍和肺动脉高压的早期发现
- 批准号:
10585312 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别:
Pterygopalatine Fossa (PPF) Block as an Opioid Sparing Treatment for AcuteHeadache in Aneurysmal Subarachnold Hemorrhage
翼腭窝 (PPF) 阻滞作为阿片类药物节省治疗动脉瘤性蛛网膜下腔出血的急性头痛
- 批准号:
10584712 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别:
An mHealth Approach to Decreasing Opioid Abuse and Other Diseases of Despair in Rural Populations
减少农村人口阿片类药物滥用和其他绝望疾病的移动医疗方法
- 批准号:
10761061 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别:
NeuroMAP Phase II - Circuits and Molecules Core
NeuroMAP II 期 - 电路和分子核心
- 批准号:
10711137 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别:
Long-term Neuropsychiatric Sequelae of SARS-CoV-2 Infection in Late Life
晚年 SARS-CoV-2 感染的长期神经精神后遗症
- 批准号:
10586560 - 财政年份:2023
- 资助金额:
$ 11.85万 - 项目类别: